Shares in Verve Therapeutics ( VERV -0.54%) soared 80.5% this week on the news of an agreement for Eli Lilly ( LLY -2.54%) to ...

Deal would add a potential treatment for cardiovascular disease to Eli Lilly’s portfolio.

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

South Korea's trade minister Yeo Han-koo will visit the United States from June 22 to 27, the trade ministry said on Saturday ...

Lilly confirmed it would buy a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.

Verve Therapeutics, Inc. (NASDAQ:VERV) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Eli Lilly and ...

(Reuters) -Drugmaker Eli Lilly is in advanced talks to acquire gene-editing startup Verve Therapeutics for up to $1.3 billion ...

HealthDay News — Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives Lilly a potential new treatment for heart disease, The Wall ...

B Verve Therapeutics (VERV) acquisition offers investors a 70%+ premium. See why I think this deal is beneficial to both ...

Eli Lilly (LLY) will acquire Verve Therapeutics (VERV) for up to $13.5/share, aiming to revolutionize cholesterol treatment.

Shares of Verve Therapeutics (NASDAQ: VERV) were skyrocketing 75.7% higher as of 10:50 a.m. ET on Tuesday. Eli Lilly (NYSE: ...

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of ...